Clinical Trials
14
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants
- First Posted Date
- 2018-11-29
- Last Posted Date
- 2018-11-29
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT03758339
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer
- Conditions
- Advanced Ovarian CarcinomaAdvanced Breast Carcinoma
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT02270372
- Locations
- 🇺🇸
UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸NYU Perlmutter Cancer Center, New York, New York, United States
Phase 1b Maintenance Therapy Study of ONT-10 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT01978964
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers, Dallas, Texas, United States
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
- First Posted Date
- 2012-06-11
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01616199
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸New York University, New York, New York, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Phase 1 Study of ONT-10 in Patients With Solid Tumors
- Conditions
- Solid Tumors
- First Posted Date
- 2012-03-16
- Last Posted Date
- 2018-05-17
- Lead Sponsor
- Cascadian Therapeutics Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01556789
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Mary Crowley Cancer Research Center, Dallas, Texas, United States
🇺🇸Northwest Medical Specialties, PLLC, Tacoma, Washington, United States
- Prev
- 1
- 2
- 3
- Next